Alliance Global Partners raised the firm’s price target on Tonix Pharmaceuticals (TNXP) to $65 from $11 and keeps a Buy rating on the shares. After having recently caught up with management to discuss the ongoing pipeline development, especially the pending potential approval of TNX-102 SL for fibromyalgia, which has a PDUFA date set for August 15, the firm notes that its sum-of-the-parts valuation includes TNX-102 SL for fibromyalgia valued at $52 per share, the Zembrace/Tosymra program valued at $1 per share, and cash and tech value of $12 per share.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNXP:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue